VNS Therapy™ for Drug-Resistant Epilepsy (DRE)
Drug-resistant epilepsy affects patients in many ways1. Find out how VNS Therapy could help to reduce the consequences of DRE for your patients.
VNS Therapy™ is an established neuromodulation therapy for DRE2, indicated for both adult and paediatric patients with focal or generalized seizures.
Highest number of publications among neuromodulation therapies in epilepsy4
High number of neuromodulation implants for DRE3
Years of experience
The longest experience in DRE
Sustained improvements in seizure frequency, seizure severity and postictal recovery7
Lower incidence of hospitalisations, A&E visits, fractures and head traumas8
Reduction of symptoms associated with depression such as mood9
Improvements in quality of life10
Improved cognitive development and memory11
Long-term efficacy of VNS Therapy™ increases over time
Studies show that VNS Therapy has been proven to reduce seizure frequency and improve other QOL related patient outcomes. The long-term efficacy of VNS Therapy increases over time13.
What is VNS Therapy™ and how does it work?
VNS Therapy is an approved treatment option for both paediatric and adult patients with drug-resistant epilepsy.
The VNS Therapy System includes a pulse generator that is implanted under the skin and connected via leads to the left vagus nerve at the carotid sheath. The generator sends mild pulses through the vagus nerve to the brain. VNS Therapy can lead to fewer seizures, shorter seizures and better recovery after seizures15.
Helps to reduce seizures
Stimulation is delivered at regular intervals all day, every day, to help reduce seizures16
Responds to rapid increases in heart rate*
An extra dose of therapy is automatically delivered at the sign of a rapid increase in heart rate, which may be associated with seizures16
*Only available in Models 106, 1000 and 1000-D
Delivers On-Demand Treatment
Stimulation is manually delivered by swiping the VNS Therapy™ magnet over the generator to help stop or shorten a seizure once it starts16
Day & Night Programming
Create two independent sets of therapy parameters at different times during a 24-hour period.
After the Day-Night program has been defined, the generator will alternate between the 2 independent parameter sets on a daily basis. This feature provides the physician with the ability to further customise the delivery of VNS Therapy to accomodate each individual patient's needs after a target level has been established for the patient.17
Enables the programming of the generator so that it automatically increases stimulation therapy parameters while the patient is in the comfort of their home.
This feature is intended to be used during the titration phase and could potentially reduce the number of appointments the patient may need to travel to and from the clinic for programming visits only.17
VNS Therapy™ Potential Mechanisms of Action
1. Park KM et al, 2019. Journal of Epilepsy Research. 9:14-26 2. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 3. Data on File, LivaNova, Houston, TX 4. The number of publications/clinical trials on www.pubmed.com while searching for a. "Vagus nerve stimulation" OR "Vagal nerve stimulation" OR "VNS" AND "Epilepsy" NOT "Auricular" ; b. "deep brain stimulation" OR "DBS" AND "Epilepsy"; c. "Responsive neurostimulation" OR "RNS" AND "Epilepsy". 7. Orosz et al 2014. Epilepsia 55(10):1576-1584 8. Helmers et al, 2011. Epilepsy & Behaviour 22(2):370-5 9. Spindler et al, 2019. Seizure, 69:77-79 10. Ergene et al, 2000. Epilepsy & Behaviour, 2:284-287. Ryvlin et al, 2014. Epilepsia, 55(6):893-900 11. Orosz et al 2014. Epilepsia 55(10):1576-1584 12. Soleman et al, 2018. Epilepsy & Behaviour, 88:138-145 13. Kawai et al, 2018. Epileptic Disord, 19(3):327-38 14. Data on File, LivaNova, Houston, TX 15. Patient’s Guide for Epilepsy, November 2021, 1 — 26-0009-9700/4 (OUS) 16. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 17. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 18.Marrosu F, et al, 2005. Clin Neurophysiol. 116(9):2026 36. 19. Ravan et al, 2017. DOI 10.1109/TBME.2016.2554559, IEEE Transactions on Biomedical Engineering 20. Boon et al, 2015. Seizure 32:52–61. 21. Fisher et al, 2015. Acta Neurol Scand 131: 1–8 DOI: 10.1111/ane.12288. 22. Hallböök T, et al, 2005. Seizure 14(8):527 33. 23. Marrosu et al, 2003. Epilepsy res. 55,59-70 24. Larsen LE, et al 2016. Neurotherapeutics 13:592–602. 25. Liu WC et al,2003. J Neurol Neurosurg Psychiatry 74:811-813. 26. Dorr AE et al, 2006. J Pharmacolo Exp Ther; 318(2): 890-8. 27. Nosaka 1984. Experimental Neurol. 85:493-505. 28. Morais et al, 2020. PAIN 161 (2020) 1661–1669. 29. Kwan P, Brodie M 2000. New England Journ of Medicine. 342(5): 314-319.